Research Spotlight: Comparison of Single-Cell Profiling Methods Reveals Strengths and Limitations
The study will help researchers more efficiently approach projects employing single cell RNA sequencing on human cancer biopsies.
Department of Medicine
Allegretti Lab: Andrew Allegretti, MD, MSc
Our lab at Massachusetts General Hospital focuses on improving the health of patients with liver and kidney disease, as well as supporting patients with critical illness.
Allegretti Lab: Andrew Allegretti, MD MSc
Suite 302
165 Cambridge Street
Boston,
MA
02114
Phone: 617-726-5050
Fax: 617-724-1122
Email: aallegretti@mgh.harvard.edu
Explore This Research Lab
Overview
Andrew S. Allegretti, MD, MSc, is an Associate Professor of Medicine at Harvard Medical School and is the Director of Critical Care Nephrology at Massachusetts General Hospital. He is a Principal Investigator in the MGH Kidney Research Center and the Chair/Founder of the HRS-HARMONY Research Collaborative. He received his undergraduate and medical degrees from Brown University. He completed Internal Medicine Residency at Massachusetts General Hospital, Nephrology Fellowship in the combined program at Brigham and Women’s and Massachusetts General Hospitals, and received a Master of Science in Epidemiology from the Harvard School of Public Health.
Dr. Allegretti’s research has provided key epidemiologic and clinical observations that have affected clinical practice. His work has been cited in multiple national and international clinical practice guidelines in both liver and kidney disease. This includes research around renal replacement therapy in cirrhosis, kidney function before and after transjugular intrahepatic portosystemic shunt (TIPS) placement, and outcomes around acute kidney injury and liver transplantation. His lab studies patient phenotypes to identify sources of inflammation and endothelial cell dysfunction as novel mechanisms of hepatorenal syndrome and advanced liver disease. His work at the beside has resulting in advancements in continuous renal replacement therapy, including development of novel anticoagulation strategies and delivery of accelerated venovenous hemofiltration (AVVH), also called prolonged intermittent renal replacement therapy.
Dr. Allegretti has served as lead PI and on steering committees for multiple national and international randomized clinical trials. His work has been supported by awards from the National Institutes of Health, American Heart Association, American Association for the Study of Liver Diseases, and the American College of Gastroenterology.
Additional Information
Primary Researcher
-
![]()
- Director of Critical Care Nephrology, Massachusetts General Hospital
- Associate Professor of Medicine, Harvard Medical School
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.